Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

Eric L. Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi, Richard J. O'Brien, Andrew N. Vernon, Richard E. Chaisson, William R. Bishai, Jacques H. Grosset

Research output: Contribution to journalArticlepeer-review


Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves the sterilizing activity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereby enhancing treatment completion rates and preserving precious public health resources. The new 8-methoxyfluoroquinolone moxifloxacin has potent activity against both actively multiplying and nonactively multiplying tubercle bacilli. Using a murine model that is representative of chemotherapy for human tuberculosis, we show that the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen of isoniazid, rifampin, and pyrazinamide. The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

Original languageEnglish (US)
Pages (from-to)421-426
Number of pages6
JournalAmerican journal of respiratory and critical care medicine
Issue number3
StatePublished - Feb 1 2004
Externally publishedYes


  • Fluoroquinolone
  • Mouse
  • Moxifloxacin
  • Treatment
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis'. Together they form a unique fingerprint.

Cite this